Freeze‐Drying Tumor Tissues Derived Bio‐Patches With Hair Melanin Nanoparticles Integration for Wound Healing

Why It Matters

By merging natural tumor ECM with melanin’s bioactive properties, the patch offers a scalable, multifunctional wound‑care option that could lower infection rates and accelerate healing for refractory injuries.

Key Takeaways

• Decellularized tumor ECM retains growth factors
• Hair melanin nanoparticles provide antioxidant activity
• Photothermal effect kills bacteria on wound
• Patch accelerates angiogenesis and tissue remodeling
• Potential for treating refractory chronic wounds

Pulse Analysis

Wound‑care technology has long struggled to replicate the complex biochemical cues of native tissue. Traditional synthetic dressings lack the native extracellular matrix (ECM) that guides cell behavior, while biologically derived scaffolds often lose critical proteins during processing. Decellularization of tumor tissue preserves a rich ECM reservoir, including collagen, fibrin, and growth factors, offering a more physiologically relevant scaffold. This approach leverages the abundant supply of resected tumor specimens, turning medical waste into a therapeutic asset.

The integration of hair‑derived melanin nanoparticles (HNPs) adds a dual‑function layer to the bio‑patch. Melanin naturally scavenges reactive oxygen species, mitigating oxidative stress that impedes healing. When exposed to near‑infrared light, HNPs generate localized heat, delivering photothermal antibacterial action without systemic antibiotics. Embedding HNPs within a GelMA hydrogel matrix ensures uniform distribution and sustained release, creating a smart dressing that both protects the wound and actively combats infection.

Clinically, this technology could reshape management of chronic and refractory wounds, such as diabetic ulcers or pressure injuries, where infection and poor vascularization are major hurdles. Faster angiogenesis and reduced inflammation translate to shorter hospital stays and lower healthcare costs. As regulatory pathways for decellularized tissue products mature, the dFCT‑HNPs‑GelMA patch may attract investment and partnerships, positioning it as a next‑generation, multifunctional wound‑healing platform. Its scalable production from discarded tumor tissue further enhances commercial viability.